#Abu Dhabi #United Arab Emirates #Immunotherapy #Precision Oncology #Likang Life Sciences

Likang Life Sciences Showcases Innovations in Cancer Treatment

Likang Life Sciences is set to make a significant impact at the upcoming Abu Dhabi Future Health Summit 2026, which will take place from October 20–22 at the ADNEC Centre in Abu Dhabi, UAE. As both an exhibitor and a key sponsor, the company aims to highlight its advancements in personalized cancer immunotherapy. This event, orchestrated by the Department of Health – Abu Dhabi (DoH), will bring together a diverse assemblage of policymakers, researchers, clinicians, and industry leaders from approximately 100 nations.

Under the guiding theme, “To Sense Is to Predict,” the summit will focus on groundbreaking topics including artificial intelligence, genomics, and advanced diagnostics in the context of personalized healthcare. With over 175 organizations expected to participate, this summit provides an excellent platform for Likang to share its innovations and network with global experts.

On October 21, Shannon Cheung, the Co-Founder and Vice Chairman of Likang, will participate in a panel discussion titled “The Future of Cancer.” This discussion will explore the latest advancements in precision oncology and the essential role of innovative cancer treatments in clinical practice. The emphasis will be on how research, investment, and effective policy can lead to significant improvements in patient care.

Advancements in Personalized Immunotherapy

Likang Life Sciences is renowned for its pioneering work in the field of personalized cancer treatments. Utilizing an AI-powered neoantigen discovery platform, the company is developing innovative therapies targeting specific tumor characteristics. Their method prioritizes the identification of patient-specific tumor neoantigens, paving the way for personalized therapeutic cancer vaccines and neoantigen-specific T-cell therapies.

The lead investigational product from Likang, LK101, exemplifies this cutting-edge approach. This personalized neoantigen mRNA-DC therapeutic cancer vaccine has already achieved substantial milestones, with clinical trial authorization from China's National Medical Products Administration (NMPA) received in 2023, and U.S. FDA Investigational New Drug (IND) clearance achieved in 2025. Such breakthroughs showcase the company's commitment to translating research findings into practical medical solutions.

Collaborative Opportunities and Future Directions

At the summit, Likang will not only present its innovative technologies but will also seek to forge collaborations with international healthcare institutions and research partners, particularly within Abu Dhabi’s burgeoning precision medicine ecosystem. The objectives are clear: to accelerate the development of personalized cancer immunotherapies and to enhance global networks aimed at sharing knowledge and resources to combat cancer more efficiently.

Likang's participation in the summit underscores its dedication to driving forward the conversation around personalized cancer care. By engaging with peers and potential partners, the company hopes to leverage insights gained to refine its approach, further advancing the field of cancer immunotherapy.

About Likang Life Sciences

Founded on the principles of innovation and collaboration, Likang Life Sciences focuses on developing AI-driven personalized cancer therapies. By integrating bioinformatics, genomics, and advanced immunotherapy technologies, the company is committed to offering tailored treatments based on individual tumor characteristics. Their robust pipeline features both personalized neoantigen therapeutic vaccines and neoantigen-specific T-cell therapies, ensuring that they are at the forefront of the fight against cancer.

To learn more about Likang Life Sciences and their initiatives, please visit www.likanglife.com.